RESEARCH PAPER

CRISPR-Cas9 Technology in Genetic Disorders: Genome Editing Approaches and Therapeutic Applications – A Review

Manisha Veer[1], Poonam Nikam[1], Omkar More[2], Rajmani Shabadi[1*]

[1]Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatan, Post: Somathane, Panvel, Mumbai-410206, Maharashtra, India.

[2]Lokmangal College of Pharmacy, Wadala, Solapur, Maharashtra, India.

***Corresponding author: Dr. Rajmani Rajesh Shabadi, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatan, Post: Somathane, Panvel, Mumbai-410206, Maharashtra, India**
Email: shabadirajmani670@gmail.com
Received: 30th May, 2026; **Revised:** 10th June, 2026; **Accepted:** 15th June, 2026; **Available Online:** 18th June, 2026

ABSTRACT

Background

CRISPR-Cas9 technology has become a revolutionary tool in molecular biology and has transformed the landscape of genetic research and therapeutics. CRISPR has allowed for an unprecedented opportunity to target, modify and correct disease-causing mutations at the source, given the rapid, efficient and precise modifications of these DNA sequences. The simplicity and versatility of CRISPR, especially in comparison to previous gene editing platforms such as zinc-finger nucleases and TALENs, is appealing to today's researchers and clinicians, making CRISPR a preferred gene-modifying strategy for laboratory studies, and a pathway for future clinical trials.

Scope

This review describes the potential application of CRISPR technology for the possible management of genetic-based conditions. This review will focus on monogenic disorders, including sickle-cell anemia, β-thalassemia, cystic fibrosis, and Duchenne muscular dystrophy. Strategies using CRISPR are currently being evaluated in in vivo approaches and ex vivo approaches using patient-derived cells. The advantages of CRISPR, including precision, specificity, and potential cure, are compared with the disadvantages of traditional gene therapy, including inefficiency, costs, and immune difficulties.

Challenges

Possible problems with CRISPR technology and applications also remain. Off-target effects and incomplete edits are based on safety issues/concerns for long-term consequences. Bioethics issues, including germline editing and possible uses for enhancement of non-therapeutic applications, require even stricter oversight and regulation.

Keywords: CRISPR-Cas9, Genome Editing, Genetic Disorders, Gene Therapy, Monogenic Diseases, Ethical Issues.

How to cite this article: Veer M, Nikam P, More O, Shabadi R. CRISPR-Cas9 Technology in Genetic Disorders: Genome Editing Approaches and Therapeutic Applications – A Review. Int J Drug Deliv Technol. 2026;16(61s):1018-1027. DOI: 10.25258/ijddt.16.61s.112
Source of support: Nil.
Conflict of interest: None



GRAPHICAL ABSTRACT

INTRODUCTION

Over the last century, genetics has dramatically evolved, with a series of discoveries advancing our fundamental knowledge of heredity, variation, and disease. Much was discovered about DNA, including the recognition of it as the genetic material in the mid-20th century, while the completion of the Human Genome Project at the turn of the millennium advanced our knowledge of the genetic blueprint of life. Many developments

have emerged from the field of molecular biology, with genome editing being one of the most influential developments to date, as it provides the ability to break the disease chain by potentially fixing the mutation causing the disease. Among genome editing techniques, the CRISPR-Cas9 system has quickly gained ground as the most effective, versatile, and widely adopted method for targeting modifications of a gene. The adaptability, specificity, and relatively low cost of CRISPR-Cas9 is revolutionizing both basic research and treatment of diseases, particularly, genetic diseases.

The advancements surrounding genome editing started with the discovery of restriction endonucleases in the 1970s. Restriction endonucleases are enzymes, also known as the "molecular scissors" of bacteria, that cut DNA at recognized sites. This finding laid the foundations for recombinant DNA technology and provided for the formation of genetically modified organisms (GMOs) and eventually gene therapy research. Restriction enzymes are not flexible because they only cut DNA at predetermined sequenes.

Engineered nucleases represent the next advancement, which included nucleases such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), which provide more control over the target DNA sequences. Although ZFNs and TALENs were a great advance, they were labor intensive, expensive to design, and difficult to engineer, making them suboptimal

Historical Evolution of Genome Editing

with their limited efficiency due to complex engineering.

The identification of clustered regularly interspersed short palindromic repeats (CRISPR) in bacteria marked a turning point. First detected in the late 1980s as unusual repeating sequences in microbial genomes, the function of CRISPR was unknown for many years; however, by the early 2000s CRISPR was identified as a mechanism used by bacteria and archaea as a defense strategy against viral infection. Microbes are able to incorporate fragments of viral DNA into their own genome, creating a "genetic memory" of foreign attack to recognize and ultimately defend against future viral attacks. The Cass (CRISPR-associated) proteins, particularly Cas9, were determined to be necessary components of this immune response as they act to cleave foreign DNA in a sequence-specific manner.

In 2012, Jennifer Doudna and Emmanuelle Charpentier demonstrated that CRISPR-Cas9 could be programmed to a target a virtually any DNA sequence using a short RNA molecule as a guide. This revolutionary discovery propelled CRISPR from an interesting microbial phenomenon and curiosity to a

new and exciting method for genome editing. Doudna and Charpentier were awarded the Nobel Prize in Chemistry in 2020 for their landmark discovery.

Mechanism of the CRISPR-Cas9 System

At the most basic level, the CRISPR-Cas9 system can be considered a programmable nuclease complex. The CRISPR-Cas9 system can be broken down into two basic parts: a guide RNA (gRNA) and the Cas9 nuclease. The gRNA complements a particular target DNA sequence. Once the gRNA has matched with its exact compliment, the Cas9 protein will create a double strand break in the target DNA sequence at the site required. The cell's DNA repair mechanism will initiate the DNA repair process either via "non- homologous end joining (NHEJ)", which usually will disrupt the target gene or "homology directed repair (HDR)" which will represent an intersection, or even a correction of specific target sequences, if a repair template is available for HDR.

This fairly simple but effective mechanism allows researchers to knock out genes, insert new sequences, or correct pathogenic mutations. While prior genome editing technologies exist, the simplicity of design and accessibility of CRISPR is what has made it rapidly adopted by researchers worldwide for a variety of applications.

Types of CRISPR Systems

The CRISPR-Cas9 system is not the only widely known and utilized system type, many different CRISPR variants exist. CRISPR systems are classified according to the complexity of their structure and the relevant effector proteins.

• Class 1 Systems are multi-protein complexes that recognize and cleave DNA. Class 1 systems are not widely used for genome editing applications due to their complexity.

• Class 2 Systems use a single effector proteins, which makes them less complex, and thus more useful for genome editing applications. The most famous Class 2 example is Staphylococcus pyogenes Cas9, but other proteins in the class have been established for editing application, including Cas12 (Cpf1) and Cas13.

Cas9 : The usage of the Cas9 enzyme still serves as the backbone of DNA manipulation; the Cas12 enzyme provides several advantages including making staggered cuts and providing additional options for DNA manipulation. The Cas13 enzyme provides specific advantages because it targets RNA instead of DNA which allows for temporary gene expression regulation without modifying the genome. Additionally, base editors and prime editors, which are derivatives of CRISPR, have been developed to make precise nucleotide changes without the induction of double-strand breaks.

It makes it more likely that the risks of unwanted mutations can be minimized, and has a wider range of applications.

Ideal Characteristics of a Genome Editing Tool

A genome editing system must ideally meet the following criteria for research and clinical use:

1. Precision – The ability to target a specific genomic site with minimal off-target effects.
2. Efficiency – High probabilities of success in making the intended modifications.
3. Versatility – Ability to modify many types of mutations and genetic loci.
4. Safety – Minimal cytotoxicity, immune response, or unintended effects.
5. Accessibility - Easily designed and affordable for broad usage.
6. Reproducibility – Consistency across different cell types and organisms. CRISPR-Cas9 largely meets these requirements, making it a superior choice over earlier technologies. Its programmable nature allows scientists to rapidly design gRNAs targeting virtually any genomic sequence, while the Cas9 protein executes precise cleavage.

CRISPR-Cas9 in Genetic Disorders

Genetic disorders are caused by alterations in the DNA sequence, ranging from single-nucleotide mutations to large chromosomal rearrangements. Many of these conditions, such as sickle-cell anemia, cystic fibrosis, and Duchenne muscular dystrophy, have devastating impacts on patients and families, with limited treatment options. Traditional therapies often address only the symptoms rather than the underlying cause.By directly correcting or compensating for genetic mutations, CRISPR has the potential to offer long- lasting or even permanent cures. Research in animal models and early clinical trials has already demonstrated promising results. For instance, CRISPR has been successfully used to modify hematopoietic stem cells in patients with sickle-cell disease, reactivating fetal hemoglobin production to bypass the defective gene. Similarly, strategies are underway to restore functional dystrophin in muscular dystrophy patients and to repair defective CFTR genes in cystic fibrosis.



The Promise and Responsibility of Genome Editing

The excitement surrounding CRISPR as a potential cure for genetic disorders comes with serious ethical responsibilities and societal implications of adopting CRISPR into practice. Off-target effects—where unintended mutations could occur—mosaicism, and immune responses which may inadvertently impact patient safety illustrate that due diligence must temper excitement. Germline editing and the heritable changes that would accompany it bring even more ethical and societal questions. Should humanity alter the conservation of the human germline to prevent a variant of the disease, or is the potential for germline editing to be misused for enhancement too great?

As a result, decisions to introduce CRISPR into clinical practice must have thorough safety assessment protocols, regulatory protocols, and ethical oversight informed by the potential implications. Somatic cell editing has a wide and generally accepted social consensus in the scientific community (for the treatment of genetic disorders), however; germline editing and its implications should be subject to great global consensus before any clinical application.

Conclusion of Introduction

The scientific advancements in genetics

resulted in a revolutionary step forward in CRISPR-Cas9; this tool has the defining characteristics of precision, efficiency, and versatility. Since it is based on the adaptive immune system of bacteria, CRISPR allows for unique opportunities whereby genetic disorders can be treated in ways previously deemed impossible. CRISPR is fundamentally not a simple incremental step into medicine to treat severe genetic diseases, but a strategy that introduces entirely new opportunities in this area.

In the following sections of this paper, I will explore the immense promise and the profound complexities CRISPR presents. CRISPR offers an exciting vision of the future while demanding that we carefully navigate the rapid pace of science as we move into a new phase of genomic medicine.

IMPORTANCE

Genetic disorders represent a key public health issue facing the globe, affecting millions of individuals and causing significant morbidity and mortality. A genetic disorder is defined as a disorder resulting from one or more mutations in genes and includes sickle-cell anemia, Duchenne muscular dystrophy, cystic fibrosis, and hemophilia. Many of these disorders present early in life and involve chronic complications that lead to chronic disease and functional disability, impacting life expectancy.

Genetic disorders can carry a financial burden that has not only medical, but social and economic implications as well. Many genetic disorders result in patients requiring long-term therapy, multiple hospital visits, and / or high intensity medical care, impacting the financial situation of families and the health care system. Furthermore, caregivers of patients with genetic disorders may experience depression or grief due to the burden placed on their lives, impacting the social cost of genetic disorders.

All standard therapies for genetic disorders manage complications of the disease rather than addressing the underlying cause of the disorder. Blood transfusions and hydroxyurea have been shown to lower morbidity in sickle-cell patients, whereas antibiotics and physiotherapy mitigate the complications of cystic fibrosis. But none of these approaches can fix the original genetic defect. Even sophisticated solution such as viral- vector - based gene therapy remain limited as a financially prohibitive, safe, and effective solutions in the long-term management of a genetic disorder.

Emerging genome editing tools such as CRISPR are quite significant in our understanding of genetic disorders, as CRISPR offers - in theory - curative therapies aimed at gene-level approaches that provides for the direct correction or compensation for disease-causing mutations.

CONVENTIONAL METHODS

Prior to CRISPR's arrival on the scene, scientists used previous genome-editing tools to repair genetic defects. The early strategies utilized modified viruses to deliver healthy copies of genes into patient cells, like some gene therapies do today. Historically, this strategy was a landmark development, but it had

significant drawbacks, such as the likelihood of immunogenicity, random insertion of the gene into the genome, and limited duration of benefit (i.e., the patient needed repeated treatment due to gene expression waning over targeting specific DNA sequences, but ZFNs were exceedingly difficult and expensive to design, ultimately prohibiting their widespread use. Transcription Activator-Like Effector Nucleases (TALENs) proved an even greater advancement. TALENs gave a researcher considerable flexibility to recognize DNA sequences and also provided a user-friendly replacement over ZFNs. Although TALENs have been effective in laboratory research and profitable in some early therapeutic applications, like PALENs, they were still technically difficult, continued to be costly to build, and were otherwise insufficiently efficient for large-scale clinical applications.

In summary, despite being groundbreaking and clearly laying a foundation for current gene therapies, these earlier approaches have limitations that CRISPR has sought to overcome. INNOVATIVE APPLICATIONS OF CRISPR IN

INNOVATIVE APPLICATIONS OF CRISPR IN GENETIC DISORDERS

CRISPR-Cas9 technology has quickly changed from a laboratory project into clinical reality, providing realistic hope for previously untreatable genetic diseases. The technology is flexible and can be used by researchers to



correct point mutations, insert sequences that may be missing, or silence defective genes. The following represent the main categories of applications in CRISPR, which will be elaborated upon below.

Hemoglobinopathies (Sickle-Cell Anemia and β-Thalassemia) Sickle-cell anemia and β-thalassemia were among the first classes of genetic disorders approached with CRISPR-based therapies. Both disorders are caused by mutations in the β-globin gene that affect the function of hemoglobin. In sickle-cell anemia, the reactivation of fetal hemoglobin (HbF) via CRISPR relies on disrupting a repressor gene (BCL11A), which may bypass the ineffective adult hemoglobin and restore the functionality of the red blood cell. In β- thalassemia, CRISPR is used to repair defective β-globin gene expression (or to compensate for the defective β-globin gene expression), thereby reducing the patient's need for lifelong blood transfusions. Several clinical trials have reported positive results, with some patients having long-term relief from symptoms attributed to the CRISPR-based therapy.

Duchenne Muscular Dystrophy (DMD) is a lethal neuromuscular disorder arising from mutations in dystrophin, one of the largest genes in the human genome. The CRISPR system has been applied to restore dystrophin's reading frame (frame-shift mutations) by removing the faulty exons. While animal models have suggested improved muscle performance, preclinical studies have more closely modeled clinical applications. This application of CRISPIR is of critical importance as a curative therapy for DMD does not exist at this time, yet CRISPR may allow progress to be halted.

Cystic Fibrosis (CF) Mutations in the CFTR gene result in the production of defective chloride ion channels

- thus resulting in thick mucus buildup within the lungs and digestive tract (Beckett et al., 2021, Wang et al, 2019). Traditional therapies focus on preventing or managing infections and improving breathing, but CRISPR approaches have a direct corrective strategy. In laboratory models, CRISPR technology can be applied in different ways to correct and repair CFTR mutations within airway epithelial cells and restore chloride transport. Therefore, there is potential for genetic therapies that address the genetic defect, instead of just treating the symptoms of cystic fibrosis.

Hemophilia is caused by mutations in clotting factor genes such as Factor VIII (Hemophilia A) and Factor IX (Hemophilia B). CRISPR-based editing approaches may be used to repair or insert functional copies of these clotting factor genes in liver cells to produce normal levels of clotting factor. Animal studies have shown encouraging results, and human studies are in development. If successful, this strategy could mitigate or eliminate the need for life-long administration of a clotting factor replacement or bypass therapy.

Neurological and Metabolic Disorders In addition to genetic disorders that are easy to conceptualize as single- gene disorders, the field of CRISPR is evaluating its role in

neurological disorders and metabolic disorders:

Huntington's Disease: caused by trinucleotide repeat expansions, one potential application of CRISPR is to excise the trinucleotide repeat.

Phenylketonuria (PKU): has been assessed as a clear disorder for CRISPR interference as it corrects mutations in the PAH gene that impairs phenylalanine metabolism.Glycogen Storage Disorders: As metabolic diseases, CRISPR-based correction approaches were tested in laboratory animals to restore active metabolic enzymes.

Clinical Trials in Progress Some CRISPR therapeutics have already advanced to clinical trials, including: CTX001, from Vertex Pharmaceuticals and CRISPR Therapeutics, has been beneficial in treating both sickle- cell anemia and β-thalassemia. Other trials are

being conducted for Leber congenital amaurosis (LCA10), a type of inherited blindness, where CRISPR aims to directly correct mutations in the CEP290 gene in retinal cells.These are truly historic trials, allowing CRISPR to move from the lab bench to the patient bedside.
Research Applications Beyond direct therapy, CRISPR is also extensively utilized to establish disease models in animals, allowing researchers to study genetic disorders in pre-clinical phase much more effectively.

Not only do the models help accelerate drug discovery, but they've also provided insights into disease mechanisms.

Therapeutic Impact of CRISPR-Cas9 Genome Editing

CRISPR/Cas9 is an exciting technology that is revolutionizing genetic medicine, potentially correcting genetic disorders. CRISPR offers several advantages over traditional methods of gene therapy. CRISPR is most noted for its precision, as it can readily target and modify any specific DNA sequence with minimal off-target modifications. This increased efficiency allows for more time studying the repaired locus then conducting experiments to unravel the function of the gene of interest. One of the greatest advantages of CRISPR is its permanence. Standard gene therapies have often targeted the symptoms of genetic disorders, but with CRISPR researchers can directly repair or edit defective genes. The transition into a curative repair procedure, vs. a life-long treatment strategy represents a great advancement in medicine for patients with diseases such as sickle-cell anemia, β-thalassemia, or cystic fibrosis. CRISPR is also fundamentally easy and inexpensive to work with. Unlike previous generation technologies such as Zinc Finger Nucleases or TALENs, which required complicated protein engineering, CRISPR only requires the alteration of the guide RNA. The efficiency cuts down costs, and allows CRISPR to be more readily deployed, even in small laboratories and facilities, therefore it will facilitate faster research and ultimately greater development of new therapies. The power of CRISPR is have multiple means of delivery to repair defective genes. CRISPR can be used in an ex vivo approach, where cells from the patient are edited in vitro and re-introduced to the patient, or it can be used in an in vivo approach where the plasmid or the CRISPR components are delivered directly into the patient (e.g. patient's muscle).



DISADVANTAGES / ETHICAL ISSUES OF CRISPR IN GENETIC DISORDERS.

While CRISPR technology has immense potential, there are numerous disadvantages and ethical ramifications that need to be considered before its widespread use in the clinic. One of the largest issues is the risk of off-target effects. Even with improvements in guide RNA design, CRISPR may cut unintended genomic locations and create harmful mutations, genetic cancer, or disrupt essential genes. As such, safety issues remain a major barrier to converting laboratory success into dependable human therapies.

A second major issue is germline editing where changes are made at the embryo or reproductive cell stage. Germline editing raises the opportunity to prevent inherited diseases, but it also raises serious ethical questions. Germline edits are inheritable, which raises the ethical question of whether the edited changes

will be passed on to future generations without their consent. Among others, this brings about concerns over human rights, the ethics of any medical intervention or investigational procedure, stealing the rights of the next generation of humans, and the potential misuse of this life-altering technology. Designer babies has received a large amount of notoriety since it presents the opportunity to enhance traits like intelligence, appearance, or even athletic ability; this has caused significant controversy around the world.

The clinical uses of CRISPR are also limited by regulatory and societal issues. Different countries operate under vastly different legal and ethical frameworks which make it a challenge to govern CRISPR with consistency. Finally, public perception can also be difficult, as many people are unaware of an awareness the implications of genetic manipulation and potential risks that come along with the use of

CRISPR.



FUTURE SCOPE.

The future of CRISPR technology related to genetic disorders is incredibly exciting and as current advances continue to increase safety, precision, and applicability, the potential is very high. Research as of now is focused around base editors and prime editors which will provide precise single nucleotide changes in a targeted DNA rewrite without needing to induce double-strand breaks. These new methods greatly reduce the chances of unintentional mutations and create safer standards for therapies applied to humans.

Use of CRISPR alongside changes in computational approaches such as artificial intelligence (AI) and machine learning are also in development to help predict off-target effects, create more accurate guide RNAs, and improve methods of delivery for more efficient CRISPR use. Additionally, new delivery methods such as viral vectors and nanoparticles will allow CRISPR to reach new target tissues like those of the brain and muscles that were previously unable to be targeted.

At a larger level, CRISPR could facilitate personalized medicine that includes therapies selective to individuals' genetic profiles. As the use of CRISPR expands from a clinical environment to an ethical framework. There is still the need for organizational limitations around CRISPR technologies as they are applied to germline editing; the opposite could result in ambiguous therapies which could quickly become inappropriate.

Overall, the future scope of CRISPR is incredibly miraculous; creating once incurable genetic disorders into treatable or reversible situations.



CONCLUSION

CRISPR-Cas9 technology has, for all intents and purposes, provided new possibilities and new horizons in the field of genetics in the form of an effective, accurate, and cost-efficient genome editing tool. The rapid adoption of CRISPR technology in biomedical research, alongside its astounding potential, is indeed one of the most important milestones in 21st-century science. While adopting CRISPR studies in viral vectors, ZFNs, or TALENs concerning gene therapy was a huge step and carried a lot of potential, their high cost, high complexity, and low efficiency considerably limited their applicability. CRISPR, unlike these other methods, is able to resolve those inefficiencies at a lower cost.

The impact of this technology is best

illustrated through its impact on other genetic problems. Prominently, sickle-cell anemia, β-thalassemia, Duchenne muscular dystrophy, cystic fibrosis, and hemophilia have seemed to be diseases viable for treatment for a very long time, and with the aid of CRISPR technology, cure strategies are being developed and tested. The ongoing clinical trials and CRISPR technology ex vivo and in vivo approaches prove that CRISPR is no longer a theory-based technology, as it is paving pathways for advanced and effective treatments. In addition to that, CRISPR's efficiency is aiding in disease modeling, drug discovery, and pers

REFERENCES

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337(6096):816–821.

Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science*. 2014;346(6213):1258096.

Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. *Mol Ther*. 2016;24(3):430– 446.

Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. *Nat Biotechnol*. 2016;34(9):933–941.

Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering.
Cell. 2014;157(6):1262–1278.

Carroll D. Genome editing: past, present, and future. *Yale J Biol Med*. 2017;90(4):653–659.

Dever DP, Bak RO, Reinisch A, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. *Nature*. 2016;539(7629):384–389.

Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β- thalassemia. *N Engl J Med*. 2021;384(3):252–260.

Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. *Science*. 2016;351(6271):403–407.

Schwank G, Koo BK, Sasselli V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. *Cell Stem Cell*. 2013;13(6):653–658.

Wu Y, Liang D, Wang Y, et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. *Cell Stem Cell*. 2013;13(6):659–662.

Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature*. 2016;533(7603):420–424.

Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature*. 2019;576(7785):149–157.

Cox DBT, Gootenberg JS, Abudayyeh OO, et al. RNA editing with CRISPR-Cas13. *Science*. 2017;358(6366):1019–1027.

Porteus MH. A new class of medicines through DNA editing. *N Engl J Med*. 2019;380(10):947–959.